8-K: BeyondSpring Reports Q3 2025 Results, Plinabulin & SEED Progress

BeyondSpring Inc. announced its third-quarter 2025 financial results, highlighting positive clinical data for Plinabulin and significant milestones for its co-founded entity, SEED Therapeutics.

Summary

• Net loss from continuing operations for the third quarter of 2025 was $1.7 million, an improvement from $2.2 million in the same period of 2024.
• Year-to-date 2025 net loss from continuing operations was $6.2 million, compared to $6.9 million for the nine months ended September 30, 2024.
• Cash and cash equivalents significantly increased to $12.5 million as of September 30, 2025, from $2.9 million as of December 31, 2024.
• Plinabulin demonstrated an 85% disease control rate and a median progression-free survival (PFS) of 7.0 months in a Phase 2 study for metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors.
• A Phase 1 study showed Plinabulin achieved a 54% disease control rate across eight cancer types, promoting DC maturation and M1 macrophage polarization via a GEF-H1-dependent mechanism.
• SEED Therapeutics, co-founded by BeyondSpring with a 38% equity share, successfully completed a $30 million Series A-3 financing round.
• SEED Therapeutics received U.S. FDA and China NMPA Investigational New Drug (IND) clearance for its lead RBM39 degrader program.
• SEED Therapeutics was named a finalist for the 2025 Prix Galien USA Best Start-Up Award.
• Research and development (R&D) expenses for continuing operations increased to $1.0 million in Q3 2025 (from $0.6 million in Q3 2024) and to $2.9 million year-to-date 2025 (from $2.2 million year-to-date 2024).
• General and administrative (G&A) expenses for continuing operations decreased to $0.8 million in Q3 2025 (from $1.7 million in Q3 2024) and to $3.4 million year-to-date 2025 (from $4.9 million year-to-date 2024).
• Net income attributable to BeyondSpring Inc. for the nine months ended September 30, 2025, was $1.1 million, a significant improvement from a net loss of $9.4 million in the prior year period.
• Basic and diluted earnings per share (EPS) for BeyondSpring Inc. was $0.03 for the nine months ended September 30, 2025, compared to a loss of $0.24 in the prior year period.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for Plinabulin, significant progress and financing for SEED Therapeutics, and improved financial performance with reduced net losses and a substantial increase in cash, leading to a net income attributable to BeyondSpring Inc. for the year-to-date. While R&D expenses increased, this is offset by G&A reductions and overall positive developments.

Positives

• Cash and cash equivalents increased significantly to $12.5 million as of September 30, 2025, from $2.9 million at December 31, 2024.
• Net loss from continuing operations decreased to $1.7 million in Q3 2025 from $2.2 million in Q3 2024, and to $6.2 million year-to-date 2025 from $6.9 million year-to-date 2024.
• Achieved a net income attributable to BeyondSpring Inc. of $1.1 million for the nine months ended September 30, 2025, a substantial improvement from a $9.4 million net loss in the prior year period.
• Basic and diluted EPS for BeyondSpring Inc. turned positive at $0.03 for year-to-date 2025, compared to a loss of $0.24 in the prior year period.
• Plinabulin demonstrated encouraging efficacy in a Phase 2 study for metastatic NSCLC patients who progressed on prior PD-1/L1 inhibitors, achieving an 85% disease control rate and 7.0 months median PFS.
• Plinabulin showed a 54% disease control rate across eight cancer types in a Phase 1 study, with a mechanism involving DC maturation and M1 macrophage polarization.
• SEED Therapeutics, a co-founded entity, successfully completed a $30 million Series A-3 financing round.
• SEED Therapeutics received U.S. FDA and China NMPA IND clearance for its lead RBM39 degrader program, advancing it into clinical development.
• SEED Therapeutics was recognized as a finalist for the 2025 Prix Galien USA Best Start-Up Award.
• General and administrative expenses decreased by $0.9 million in Q3 2025 and $1.5 million year-to-date 2025 due to lower administrative headcount and professional service costs.
• BeyondSpring Inc.'s shareholders deficit improved (became less negative) from ($32.9 million) as of December 31, 2024, to ($31.8 million) as of September 30, 2025.

Negatives

• Research and development expenses for continuing operations increased by $0.4 million in Q3 2025 and $0.7 million year-to-date 2025, primarily due to higher drug manufacturing and professional service expenses.
• Net loss from discontinued operations increased to $3.2 million in Q3 2025 from $2.4 million in Q3 2024.
• Current assets of discontinued operations significantly decreased to $11.4 million as of September 30, 2025, from $25.3 million as of December 31, 2024.
• Total liabilities increased from $48.6 million as of December 31, 2024, to $49.3 million as of September 30, 2025.
• Total shareholders deficit (including noncontrolling interests) increased from ($14.3 million) as of December 31, 2024, to ($19.8 million) as of September 30, 2025.

Risks

• Difficulties raising the anticipated amount needed to finance future operations on terms acceptable to the company, if at all.
• Unexpected results of clinical trials.
• Delays or denial in the regulatory approval process.
• Results that do not meet expectations regarding the potential safety, ultimate efficacy, or clinical utility of the company's product candidates.
• Increased competition in the market.
• The company's ability to meet Nasdaq's continued listing requirements.

Future Outlook

BeyondSpring continues to advance Plinabulin as an immune-modulating therapy for NSCLC and other cancers, with the goal of resensitizing tumors resistant to checkpoint inhibitors. SEED Therapeutics is progressing its RBM39 molecular-glue degrader into clinical development following IND clearance, aiming to address undruggable targets and unmet medical needs. The company is also supporting strategic business development and partnership initiatives for Plinabulin combination therapies.

Management Comments

• "With over 700 patients treated, Plinabulin continues to demonstrate a favorable safety profile and meaningful potential as an immune-modulating therapy with unique mechanism of dendritic cell (DC) maturation and T cell priming." Dr. Lan Huang, Co-Founder, Chair and Chief Executive Officer of BeyondSpring.
• "Plinabulin offers new hope for patients with NSCLC and other cancers whose disease progresses after checkpoint inhibitors, presented at recent SITC conference." Dr. Lan Huang.
• "Results from our global Phase 3 DUBLIN-3 trial, published in The Lancet Respiratory Medicine, showed that Plinabulin in combination with docetaxel achieved durable survival benefits and reduced chemotherapy-induced neutropenia, reinforcing its potential to advance the standard of care and drive long-term value creation." Dr. Lan Huang.
• "At SEED, which we co-founded with Lilly five years ago, we are excited that our RBM39 molecular-glue degrader has received IND clearance from both the US FDA and China NMPA." Dr. Lan Huang.
• "It is such an honor to be the only target protein degradation company nominated by the Prix Galien Foundation, recognizing our commitment to developing transformative medicine for patients." Dr. Lan Huang.
• "We are also grateful for the support of our investors and collaborators, including Lilly and Eisai, and clinicians from leading US institutions, as we work together to advance molecular glue development to address undruggable targets for patients with unmet medical needs." Dr. Lan Huang.

Industry Context

BeyondSpring operates in the highly competitive biopharmaceutical sector, focusing on oncology with its lead asset, Plinabulin, and through its significant stake in SEED Therapeutics, which specializes in targeted protein degradation. Plinabulin's unique mechanism of dendritic cell maturation and T cell priming positions it as a potential solution for overcoming resistance to existing immune checkpoint inhibitors, a critical challenge in cancer treatment. SEED Therapeutics' work on molecular glue degraders for 'undruggable' proteins represents a cutting-edge area of drug discovery, attracting significant interest and collaboration from major pharmaceutical companies like Eli Lilly and Eisai, indicating its potential to address high unmet medical needs and drive innovation in the industry.

Comparison to Industry Standards

• The 85% disease control rate and 7.0 months median PFS for Plinabulin in metastatic NSCLC patients who progressed on prior PD-1/L1 inhibitors are encouraging, especially given this challenging, heavily pre-treated patient population where typical response rates are often low and treatment options are limited.
• The IND clearance for SEED Therapeutics' RBM39 degrader positions it among a select group of companies advancing molecular glue degraders into clinical trials, a field that is still relatively nascent but rapidly growing, with companies like Kymera Therapeutics and Arvinas also making progress in targeted protein degradation.
• Being named a finalist for the 2025 Prix Galien USA Best Start-Up Award for SEED Therapeutics indicates strong industry recognition for its innovative approach and potential impact, placing it among top emerging biotech companies.

Related Party Transactions

• BeyondSpring co-founded SEED Therapeutics with Lilly five years ago and currently holds approximately 38% equity share.
• BeyondSpring entered into definitive agreements in January 2025 to sell the majority of its Series A-1 Preferred Shares in SEED Therapeutics, which will reduce its ownership to approximately 14% upon completion of future sale transactions.
• Lilly and Eisai are mentioned as investors and collaborators of SEED Therapeutics.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial results (reduced net loss, increased cash, YTD net income), positive clinical data for Plinabulin, and successful financing/IND clearance for SEED Therapeutics, potentially increasing company valuation and future prospects.
• Patients: New hope for patients with NSCLC and other cancers, especially those who have progressed on prior checkpoint inhibitors, due to Plinabulin's encouraging clinical data and unique mechanism. Potential for new therapies from SEED Therapeutics targeting 'undruggable' proteins.
• Employees: Decreased administrative headcount led to lower salary expenses, indicating potential workforce adjustments in G&A. Increased R&D expenses suggest continued investment in scientific staff.
• Collaborators/Investors (Lilly, Eisai, SEED investors): Validation of their investment and collaboration with SEED Therapeutics through successful financing, IND clearance, and industry recognition.

Next Steps

• Continue late-stage clinical development of Plinabulin as an anti-cancer agent in NSCLC and other indications.
• Advance SEED Therapeutics' lead RBM39 degrader program into clinical development following U.S. FDA and China NMPA IND clearance.
• Further research into Plinabulin combination therapies to support strategic business development and partnership initiatives.
• Collaborate with investors (Lilly, Eisai) and clinicians from leading U.S. institutions to advance molecular glue development.

Key Dates

Recommendation

The filing indicates a strong positive trajectory for BeyondSpring. The significant improvement in financial health, moving from a substantial net loss to a net income attributable to the company year-to-date, coupled with a substantial increase in cash, demonstrates effective financial management and successful asset monetization (SEED share sale). The clinical data for Plinabulin, particularly the high disease control rate in a challenging NSCLC patient population, suggests strong therapeutic potential and de-risks the asset. Furthermore, the progress of SEED Therapeutics, including a successful $30 million financing round and IND clearance for its lead program, adds significant value and future growth potential, especially given BeyondSpring's substantial equity stake. These combined factors present a compelling investment case for a strong buy, indicating a company making significant strides in both its core pipeline and strategic investments.

Keywords

BeyondSpring, BYSI, Plinabulin, NSCLC, Cancer Therapy, Dendritic Cell Maturation, Immune-modulating, SEED Therapeutics, RBM39 degrader, Molecular Glue Degraders, Biopharmaceutical, Clinical-stage, Oncology, Financial Results, Q3 2025, SEC Filing, 8-K, FDA IND Clearance, NMPA IND Clearance, Prix Galien